KRYS Krystal Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711279 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY26.0%
TTM net income YoY13.2%
TTM EPS YoY10.3%
Revenue 3-yr CAGR280.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin48.4%
Net margin47.9%
FCF margin66.0%
EBITDA margin49.7%
Returns
ROE17.5%
ROA15.9%
ROIC (approx.)23.0%
Asset turnover0.33x
Leverage & solvency
Liabilities / assets9.5%
Debt / equity0.00x
Current ratio7.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.44x
Accruals ratio-7.0%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $127.34M | $119.22M | $116.36M | $107.11M | $97.80M | $96.04M | $88.18M | $91.14M |
| R&D expense | $14.89M | $14.52M | $15.33M | $14.79M | $14.59M | $14.41M | $14.26M | $13.53M |
| SG&A expense | $33.75M | $39.85M | $41.01M | $41.45M | $37.58M | $35.07M | $32.65M | $31.29M |
| Operating income | $71.14M | $58.42M | $53.69M | $44.27M | $41.37M | $39.40M | $36.25M | $41.38M |
| Pretax income | $80.14M | $66.08M | $61.44M | $51.13M | $47.97M | $46.77M | $43.60M | $48.61M |
| Income tax | $17.08M | $11.31M | $5.51M | -$269,000 | -$31.40M | $8.44M | $7.86M | $3.13M |
| Net income | $63.07M | $54.77M | $55.93M | $51.40M | $79.36M | $38.33M | $35.73M | $45.48M |
| EBITDA | $72.64M | $59.82M | $55.21M | $45.83M | $42.77M | $40.70M | $37.66M | $42.74M |
| EPS (basic) | 2.13 | 1.85 | 1.91 | — | 2.74 | 1.33 | 1.24 | — |
| EPS (diluted) | 2.05 | 1.79 | 1.83 | — | 2.66 | 1.29 | 1.20 | — |
| Weighted avg. shares (diluted) | 30.84M | 30.66M | 30.51M | — | 29.83M | 29.75M | 29.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $462.84M | $427.74M | $501.31M | $496.30M | $392.60M | $353.83M | $308.77M | $344.87M |
| Short-term investments | $449.01M | $417.89M | $322.09M | $331.49M | $338.46M | $328.16M | $308.08M | $252.65M |
| Receivables | $133.12M | $138.66M | $127.02M | $127.42M | $129.63M | $111.44M | $103.26M | $104.75M |
| Inventory | $50.79M | $45.56M | $42.65M | $40.48M | $37.63M | $31.04M | $29.94M | $26.51M |
| Current assets | $1.12B | $1.06B | $1.02B | $1.02B | $925.65M | $841.35M | $766.80M | $742.04M |
| PP&E, net | $152.29M | $153.78M | $153.58M | $150.78M | $148.87M | $150.39M | $151.07M | $155.17M |
| Total assets | $1.59B | $1.50B | $1.40B | $1.33B | $1.24B | $1.14B | $1.07B | $1.06B |
| Current liabilities | $142.14M | $127.40M | $107.80M | $102.94M | $91.27M | $86.90M | $79.49M | $102.00M |
| Total liabilities | $150.47M | $141.52M | $120.24M | $114.23M | $102.22M | $97.75M | $89.74M | $109.46M |
| Shareholders' equity | $1.44B | $1.36B | $1.28B | $1.22B | $1.14B | $1.04B | $984.67M | $946.38M |
| Shares outstanding | 29.63M | 29.60M | 29.44M | 29.19M | 28.98M | 28.93M | 28.90M | 28.79M |
| Cash flow statement | ||||||||
| Operating cash flow | $91.25M | $74.79M | $80.38M | $77.51M | $39.66M | $52.73M | $30.97M | $52.84M |
| Capital expenditure | $996,000 | $3.56M | $7.15M | $2.14M | $1.70M | $1.90M | $6.20M | $801,000 |
| Free cash flow | $90.25M | $71.22M | $73.23M | $75.37M | $37.95M | $50.83M | $24.77M | $52.04M |
| Investing cash flow | -$57.98M | -$161.58M | -$63.58M | $11.16M | -$4.29M | -$10.53M | -$54.77M | -$83.78M |
| Financing cash flow | $3.41M | $15.05M | -$10.46M | $15.67M | $3.71M | $1.80M | -$12.47M | $2.43M |
| Depreciation & amortization | $1.50M | $1.40M | $1.52M | $1.56M | $1.40M | $1.30M | $1.41M | $1.36M |
| Stock-based compensation | $13.94M | $14.16M | $13.61M | $13.76M | $13.15M | $14.12M | $13.48M | $13.36M |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.